| Literature DB >> 34337001 |
Deyong Ge1,2,3, Yuhan Shao3, Mengjie Wang3, Huihui Tao1,2,3, Min Mu1,2,3, Xinrong Tao1,2,3.
Abstract
Lung cancer is one of the most serious leading cancers with high incidence globally. Identifying molecular markers is key for disease diagnosis and treatment. Coal dust might be important triggering factors in disease development. Here, we first performed RNA-seq-based screening in coal dust treated and nontreated RAW264.7 cell lines. PHLDB2 was found to be the top differentially expressed gene. By retrieving TCGA lung cancer dataset, we observed that PHLDB2 showed upregulations in males and smoker patients. Patients with lower PHLDB2 expression survived longer than those with higher expressions. Furthermore, PHLDB2 was negatively correlated with EMT makers, and a total of 2.74% mutation rate were observed in 1,059 patients. This finding highlights the critical role of PHLDB2 in lung cancer development. PHLDB2 might be a molecular maker for disease diagnosis or treatment.Entities:
Year: 2021 PMID: 34337001 PMCID: PMC8314042 DOI: 10.1155/2021/1978434
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Figure 1Cell viability was tested in normal RAW264.7 cells and treated with different concentrations of dust-containing medium. All tests were replicated by more than five times. Two tail Student t-test p value was evaluated the statistical significance (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001).
Figure 2RNA-seq profile of coal dust-treated and nontreated cells. (a) Principle component analysis (PCA) revealed clear separation from treated (RA-S) and nontreated (RA-C) groups. (b) KEGG pathway analysis of 24 differentially expressed genes.
Figure 3The PHLDB2 expression in different groups. (a) The PHLDB2 expression was decreased in cancer patients compared with normal controls. Upregulated PHLDB2 levels were observed in male (b) and smoker patients (c). (d) The PHLDB2 expression in different clinical stages. Wilcox ranked test p value was used to mark the statistical significance.
Figure 4Survival analysis of patients with higher or lower PHLDB2 expression level (a) and in different clinical stages (b).
Figure 5PHLDB2 expression was negatively correlated with EMT markers (a). PHLDB2 mutation landscape in lung cancer patients from the TCGA dataset (b).